To the full analysis
Valerio Therapeutics stock: growth
ALVIO.PAValerio Therapeutics reported $2.85M in revenue for fiscal 2025, up 43.5% on the prior year.
Revenue (Annual rate)
9.5%
per year from 2006 to 2025, per share −5.7%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 7.7% | −3.0% | 9.5% |
| Revenue per share | −7.2% | −15.1% | −5.7% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $509.54K | −$14.59M | −$13.73M |
| 2007 | $3.91M | −$20.22M | −$7.72M |
| 2008 | $9.06M | −$23.68M | −$32.76M |
| 2009 | $8.35M | −$17.05M | −$19.85M |
| 2010 | $24.97M | $3.11M | $3.44M |
| 2011 | $3.58M | −$16.2M | −$13.12M |
| 2012 | $4.46M | −$12.8M | −$15.66M |
| 2013 | $1.63M | −$16.98M | −$15.67M |
| 2014 | $24.47M | −$8.53M | −$8.56M |
| 2015 | $3.86M | −$21.51M | −$25.89M |
| 2016 | $4.9M | −$25.12M | −$20.12M |
| 2017 | $10.53M | −$65.46M | −$31.41M |
| 2018 | $6.79M | −$10.42M | −$12.53M |
| 2019 | $4.75M | −$37.37M | −$8.56M |
| 2020 | $1.97M | $1.21M | −$5.32M |
| 2021 | $4.5M | −$6.58M | −$9.65M |
| 2022 | $1.6M | −$21.68M | −$11M |
| 2023 | $1.99M | −$22.54M | −$20.81M |
| 2024 | $1.99M | −$26.52M | −$14.16M |
| 2025 | $2.85M | −$5.43M | $577.32K |
Data status and sources
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 May 2024)
- Valuation signal Overvalued since 10 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.